INTRATUMORAL VEIN-FORMATION PROMOTING AGENT

• US 20190328757A1
• Filed: 06/15/2017
• Published: 10/31/2019
• Est. Priority Date: 06/17/2016
• Status: Active Application

• Current Assignee: Osaka University
• Original Assignee: Osaka University
• Inventors: TAKAKURA, Nobuyuki, EINO, Daisuke
• Application Number:
  US16/310,128
• Publication Number:
  US 20190328757A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2239/31 characterized by the route of administration
• CPC Class Codes: A61K 2239/38 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 2239/50 Colon
• CPC Class Codes: A61K 2239/55 Lung
• CPC Class Codes: A61K 2239/57 Skin; melanoma
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/513 having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• CPC Class Codes: A61K 31/685 one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• CPC Class Codes: A61K 39/395 Antibodies agglutinins A61K38/36 ; as drug carriers A61K47/50; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• CPC Class Codes: A61K 39/39541 against normal tissues, cells
• CPC Class Codes: A61K 39/461 characterised by the cell type used
• CPC Class Codes: A61K 39/4644 Cancer antigens
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/2818 against CD28 or CD152
• CPC Class Codes: C07K 16/2827 against B7 molecules, e.g. CD80, CD86

Abstract

Provided are agents comprising a phosphatidylcholine as an active ingredient to serve as a vein-formation promoting agent capable of promoting vein-like morphological change of tumor vessels, a vessel-diameter enlarging agent capable of enlarging the diameter of tumor vessels, a blood vessel-connection promoting agent capable of promoting connection of tumor vessels to each other without mediation of a lysophospholipid receptor, a leukocyte-infiltration promoting agent capable of promoting infiltration of leukocytes throughout a tumor region without mediation of a lysophospholipid receptor, and an antitumor immunostimulatory agent capable of promoting infiltration of leukocytes throughout a tumor region without mediation of a lysophospholipid receptor.

Claims

1. A vein-formation promoting agent comprising a phosphatidylcholine as an active ingredient, the agent being capable of promoting vein-like morphological change of tumor vessels.

2. The vein-formation promoting agent according to claim 1, wherein the agent is capable of enlarging the diameter of tumor vessels and/or promoting connection of tumor vessels to each other.

3. The vein-formation promoting agent according to claim 1, wherein the phosphatidylcholine is one kind of phosphatidylcholine or a mixture of two or more kinds of phosphatidylcholines.

4. The vein-formation promoting agent according to claim 1, wherein the agent is used in combination with cancer immunotherapy.

5. The vein-formation promoting agent according to claim 4, wherein the cancer immunotherapy is a therapy for reversal of immunosuppression and/or immune cell infusion therapy.

6. The vein-formation promoting agent according to claim 5, wherein the therapy for reversal of immunosuppression uses an immune checkpoint inhibitor, and wherein the immune checkpoint inhibitor is an anti-CTLA-4 antibody, a PD-1 blocker, an anti-PD-1 antibody, a PD-L1 blocker or an anti-PD-L1 antibody.

7. A vessel-diameter enlarging agent comprising a phosphatidylcholine as an active ingredient, the agent being capable of enlarging the diameter of tumor vessels.

8. A blood vessel-connection promoting agent comprising a phosphatidylcholine as an active ingredient, the agent being capable of promoting connection of tumor vessels to each other without mediation of a lysophospholipid receptor.

9. A leukocyte-infiltration promoting agent comprising a phosphatidylcholine as an active ingredient, the agent being capable of promoting infiltration of leukocytes throughout a tumor region without mediation of a lysophospholipid receptor.

10. The leukocyte-infiltration promoting agent according to claim 9, wherein the leukocytes are CD4-positive cells and/or CD8-positive cells.

11. An antitumor immunostimulatory agent comprising a phosphatidylcholine as an active ingredient, the agent being capable of promoting infiltration of leukocytes throughout a tumor region without mediation of a lysophospholipid receptor.

12. The antitumor immunostimulatory agent according to claim 11, wherein the leukocytes are CD4-positive cells and/or CD8-positive cells.